5533-02-8

Upstream product

• 5533-00-6 3-methoxy-4-methoxymethoxy-benzaldehyde 
• 350802-94-7 3-methoxy-4-methoxymethoxy-benzoic acid methoxymethyl ester 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 617-05-0 ethyl vanillate 
• 5942-32-5 ethyl 3-methoxy-4-(methoxymethoxy)benzoate 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 1161720-14-4 N,N-diethyl-3-methoxy-4-(methoxymethoxy)benzamide 
• 350802-99-2 N-(2-hydroxy-ethyl)-3-methoxy-N-(4-methoxy-benzyloxy)-4-methoxymethoxy-benzamide 
• 350802-98-1 3-methoxy-N-(4-methoxy-benzyloxy)-4-methoxymethoxy-benzamide 
• 350803-24-6 (S)-3-Hydroxy-2-(3-methoxy-4-methoxymethoxy-benzoylamino)-propionic acid methyl ester 
• 350803-30-4 (R)-3-Hydroxy-2-(3-methoxy-4-methoxymethoxy-benzoylamino)-propionic acid methyl ester 

Relevant academic research and scientific papers

Phosphoramidite containing phenolic hydroxyl, preparation method and application of phosphoramidite

The invention provides phosphoramidite containing phenolic hydroxyl and a preparation method and application of the phosphoramidite. Specifically, the invention discloses a compound shown as a formulaI, a preparation method of the compound and application of the compound serving as a solid synthesis unit. By utilizing the compound as shown in the formula I, radionuclide can be simply and efficiently labeled on nucleic acids such as aptamers, siRNAs or mRNAs, so that diagnostic reagents and therapeutic drugs are prepared.

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Vanilloid and isovanilloid analogues as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases

As aminoacyl adenylate surrogates, a series of methionyl and isoleucyl phenolic analogues containing bioisosteric linkers mimicking ribose have been investigated. Inhibition of synthesized compounds to the aminoacylation reaction by the corresponding Escherichia coli methionyl-tRNA and isoleucyl-tRNA synthetases indicated that 18 was found to be a potent inhibitor of isoleucyl-tRNA synthetase. A molecular modeling study demonstrated that in 18, isovanillate and hydroxamate served as proper surrogates for adenine and ribose in isoleucyl adenylate, respectively.